CDKN1A and malignant colon neoplasm: The transactivation specificity toward P21, MDM2, and BAX targets was confirmed with a mammalian cells-based reporter assay in colon cancer HCT116TP53−/− cells expressing mutant P53 proteins (Figure 1B).